Summit's Antibiotic Spares The Microbiome And Spoils The C Diff Rods
This article was originally published in Scrip
Summit Therapeutics' novel narrow-spectrum antibiotic ridinilazole (SMT19969) is highly effective in reducing recurrence in Clostridium difficile infections (CDI), and could address a major unmet need in the treatment of the disease, suggest Phase II data due to be presented at the ECCMID meeting in Amsterdam in April.
You may also be interested in...
Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.